Arianna Dri

Aviano, 33081, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

Journal: International journal of molecular sciences
Published: March 04, 2026

Effectiveness of azacytidine for poly ADP-ribose polymerase inhibitor-induced myelodysplastic syndrome in ovarian cancer patient: a twofold triumph.

Effectiveness of azacytidine for poly ADP-ribose polymerase inhibitor-induced myelodysplastic syndrome in ovarian cancer patient: a twofold triumph.

Journal: Journal of chemotherapy (Florence, Italy)
Published: February 12, 2026

Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study.

Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study.

Journal: Journal of geriatric oncology
Published: November 16, 2025

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Journal: Cancers
Published: July 08, 2025

The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report.

The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report.

Journal: Critical reviews in oncology/hematology
Published: January 29, 2025

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics.

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics.

Journal: Translational oncology
Published: December 15, 2024

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: September 07, 2024

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.

Journal: ESMO open
Published: August 30, 2024

Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.

Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.

Journal: Cancer treatment reviews
Published: June 21, 2024

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.

Journal: NPJ breast cancer
Published: April 28, 2024

Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].

Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].

Journal: Cancer treatment reviews
Published: March 17, 2024

Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).

Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).

Journal: Cancer treatment reviews
Published: September 09, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026